(±)-Ibipinabant

SKU: orb1302681

Description

(±)-Ibipinabant

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 362519-49-1
• MW: 487.4
• Purity: 99.83%
• Formula: C₂₃H₂₀Cl₂N₄O₂S
• SMILES: C\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1CC(C(=N1)c1ccc(Cl)cc1)c1ccccc1
• Target: Cannabinoid Receptor
• Solubility: DMSO:45 mg/mL (92.33 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.1 mM)

Bioactivity

• Target IC50:
  CB1 :22nM
• In Vivo:
  Ibipinabant (3 mg/kg) significantly lowers unfasted glucose levels compared to rimonabant at equivalent doses on days 17, 28, and 38. Long-term ibipinabant administration notably slows diabetes progression in ZDF rats by moderating the rise in blood glucose and HbA1c levels over time. Additionally, ibipinabant decreases the evident hyperinsulinemia at 6-8 weeks of age and mitigates the sharp decline in insulin levels occurring 1-2 weeks thereafter.
• In Vitro:
  Cannabinoid receptor 1 (CB1R) antagonists are promising for obesity treatment, but adverse effects limit clinical use. Ibipinabant is a potent [Ki (CB1) = 7.8 nM] and selective [Ki (CB2) = 7.943 nM] CB1 antagonist, demonstrating in vitro properties similar to rimonabant, including inverse agonism, brain penetration, and high affinity [pA2 for arachidonic acid release in CHO cells = 9.9].
• Animal Research:
  Rats: SLV319, rimonabant and rosiglitazone are suspended in a 10% dimethylacetamide, 10% cremophor, 10% ethanol and 70% water vehicle. Drugs are administered by oral gavage in a volume of 2 mL/kg body weight at 09:00 hours every day. Treatment groups are as follows: (i) Vehicle: ad libitum access to food (vehicle), (ii) Vehicle: restricted access to food (20% less than average food intake of ad libitum vehicle-treated group for the first 3 days of the study, then 10% less than the average food intake of the ad libitum vehicle-treated group for the remainder of the study) (restricted), (iii) Rosiglitazone (4 mg/kg), (iv) Rimonabant (3 mg/kg) (RIM 3 mg/kg), (v) Rimonabant (10 mg/kg) (RIM 10 mg/kg), (vi) SLV319 (3 mg/kg) (IBI 3 mg/kg) and (vii) Ibipinabant (10 mg/kg) (IBI 10 mg/kg). Rosiglitazone is used as a positive control for its ability to delay β-cell decline, and rimonabant is used as a positive control for CB1 antagonism.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

(±) Ibipinabant, (±)-BMS6462, (±)-Ibipinabant, (±)Ibipinabant, (±)-SLV319, Cannabinoid Receptor, CannabinoidReceptor, CB, CB1, BMS6462, BMS-6462, BMS 6462, inhibit, Inhibitor, Ibipinabant, SLV319, SLV-319, SLV 319

Compound Identifiers

PubChem CID

11179267